Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Other Non-Current Liabilities (2021 - 2023)

Arcturus Therapeutics Holdings' Other Non-Current Liabilities history spans 3 years, with the latest figure at $497000.0 for Q4 2023.

  • For Q4 2023, Other Non-Current Liabilities fell 82.28% year-over-year to $497000.0; the TTM value through Dec 2023 reached $497000.0, down 82.28%, while the annual FY2023 figure was $497000.0, 82.28% down from the prior year.
  • Other Non-Current Liabilities reached $497000.0 in Q4 2023 per ARCT's latest filing, down from $976000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $3.7 million in Q3 2022 to a low of $358000.0 in Q1 2021.
  • Average Other Non-Current Liabilities over 3 years is $1.5 million, with a median of $1.3 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: soared 163.7% in 2022, then plummeted 82.28% in 2023.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $1.4 million in 2021, then skyrocketed by 101.15% to $2.8 million in 2022, then tumbled by 82.28% to $497000.0 in 2023.
  • Per Business Quant, the three most recent readings for ARCT's Other Non-Current Liabilities are $497000.0 (Q4 2023), $976000.0 (Q3 2023), and $1.3 million (Q2 2023).